盘中，直线涨停！三大利好，突然引爆

Core Viewpoint - The article highlights a significant positive shift in the pharmaceutical and medical device sectors in China, driven by recent policy changes and market dynamics that favor quality over price competition, indicating a transition from a "price war" to a "value war" in the industry [2][6]. Group 1: Market Movements - On July 25, A-shares experienced slight fluctuations, with AI concept stocks showing strength, while the pharmaceutical and medical device sectors saw substantial gains, with several stocks hitting the daily limit [1]. - The CRO index surged over 3%, and the Wind Medical Device Select Index rose nearly 3%, with companies like Yiming Pharmaceutical and Tianmu Pharmaceutical reaching their daily limits [5]. Group 2: Policy Developments - The optimization of centralized procurement policies aims to curb vicious price competition, promoting a shift towards value-based competition in the pharmaceutical industry [2]. - The National Medical Insurance Administration held a meeting to discuss new measures supporting innovative drugs and medical devices, indicating a commitment to enhancing the quality of healthcare offerings [3][7]. - The Shanghai Pudong New Area government released a plan to enhance the biopharmaceutical industry park, targeting a scale exceeding 500 billion yuan by 2027 [4][9]. Group 3: Industry Outlook - Analysts suggest that the recent policy changes will lead to a recovery in valuations and performance in the medical device sector, with expectations of high growth for several companies in the third quarter [5][6]. - The National Medical Products Administration reported that China's innovative drug development pipeline accounts for about 25% of the global total, with approximately 3,000 clinical trials ongoing annually [8]. - The Pudong plan aims to establish a world-class biopharmaceutical industry park, with specific targets for innovation and market entry of new products by 2027 [9].